← Back

Heart Test Laboratories Inc. Common Stock

HeartSciences Inc. is a medical technology company focused on advancing electrocardiography (ECG) through artificial intelligence. It develops AI-enhanced ECG solutions, including an algorithm to detect impaired cardiac relaxation or cardiac dysfunction, the MyoVista wavECG resting 12-lead ECG device that provides diagnostic and conventional ECG information in a single test, and MyoVista Insights, a cloud-native, vendor- and device-agnostic ECG management platform. Formerly known as Heart Test Laboratories, Inc., it changed its name to HeartSciences Inc. in October 2024. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Price · split & dividend adjusted
News & notes moving HSCS
HSCS▲

HeartSciences Files Fiscal 2026 Annual Report on Form 10-K

HeartSciences has filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026 with the U.S. Securities and Exchange Commission. The company also expects to file shortly a preliminary proxy statement related to its proposed business combination with Fortitude Mining Holdings, a wholly-owned subsidiary of Digital Currency Group. HeartSciences believes the proposed transaction offers a significant opportunity for shareholders, providing continued ownership in a scaled, revenue-generating business while allowing its MyoVista Insights AI-ECG technology to advance with greater focus. Following the proxy filing, the company intends to issue its fiscal 2026 earnings release and a business update, currently expected early next week. CEO Andrew Simpson called fiscal 2026 a landmark year with the launch of MyoVista Insights and the beginning of a transition to mainstream commercial revenue.
HSCS ▲
HSCS · Capital · Positive Filing annual report and announcing business combination with Fortitude Mining Holdings, which offers continued ownership in a scaled, revenue-generating business.
Fortitude Mining Holdings · Capital · Positive Fortitude Mining Holdings is the acquisition target in the proposed business combination, providing a path to public listing.
Read original ↗
GlobeNewswire·73dRead more →
Biotech & Genomic Medicine

NeOnc, Boundless Bio, Backblaze, and HeartSciences announce major catalysts

Several emerging companies are approaching significant inflection points. NeOnc Technologies received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 through Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, with a Phase 2a readout expected by the end of July 2026. Boundless Bio announced a proposed merger with privately held Serapha Bio, creating a publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management. Backblaze signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with AI cloud infrastructure provider CoreWeave, positioning Backblaze as a key storage provider for portions of CoreWeave's managed storage infrastructure. HeartSciences announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash, with existing Fortitude owner Digital Currency Group expected to hold approximately 95% of the combined company upon closing.
BLZE ▲BOLD ▲HSCS NTHI ▲
Biotech & Genomic Medicine ▲Artificial Intelligence ▲
About megatrends
Biotech & Genomic Medicine › Gene & Cell Editing ▲Capital
Artificial Intelligence › AI Compute Cloud & Neoclouds ▲Demand
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Technology
BLZE · Demand · Positive Signed a five-year, $335M data storage agreement with CoreWeave.
BOLD · Capital · Positive Announced merger with Serapha Bio backed by ~$230M committed financing.
HSCS · Capital · Neutral Announced business combination with Fortitude Mining Holdings; existing owner to hold ~95%.
NTHI · Regulation · Positive Received IND authorization from Abu Dhabi health department for NEO100 program.
Read original ↗
GlobeNewswire·103dRead more →
© 2026 MarketDXAsset